The invention provides a formulation for transmucosal administration of at least one active ingredient from the setron family, the formulation comprising said active ingredient in base form and/or in salt form, a hydroalcoholic solution titrating at least 30° alcohol, and optionally a pH correcting agent, said active principle being present in the state of stable and complete dissolution in the hydroalcoholic solution. The invention also provides a method of preparing this formulation and its use for the treatment and prevention of major nausea and/or vomiting syndromes, and also for the treatment and prevention of digestive spasms.
